July 4, 2017 Clinical Research/Diagn.

Roche launches the first fully automated CE marked HIV-1/HIV-2 qualitative diagnostic test on cobas® 6800/8800 Systems

July 4, 2017   Differentiates between HIV-1 and HIV-2 infections to confidently treat patients based on HIV subtype infection Significant reduction in time to detection is critical in curbing further disease transmission Access to testing in rural areas through validated dried blood spot (DBS) collection card Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial... Read more

July 3, 2017 Clinical Research/Diagn. Life Science Tools

Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections

Basel, 03 July 2017 Roche expands cobas Liat PCR System menu with launch of cobas MRSA/SA test to target healthcare-associated infections With more than 150,000 affected patients per year, MRSA and SA are major sources of healthcare and community associated infections in Europe Fast detection reduces the risk of transmission within the hospital, but classical... Read more

June 30, 2017 PR/Corporate

Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma

Basel, 30 June 2017 Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options First PRIME designation for a... Read more

June 30, 2017 M&A, Partnerships

Roche acquires mySugr to form a leading open platform for digital diabetes management

Basel, 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management mySugr will become an integral part of Roche’s new patient-centred digital health services in diabetes care   Healthcare providers can continue to utilise existing Accu-Chek tools to make better and faster therapy decisions while improving communication with their patients... Read more

June 27, 2017 Licensing, IP, and Legal Product Launch

Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more

June 27, 2017 Licensing, IP, and Legal Product Launch

Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)

Basel, 27 June 2017 Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of Esbriet offers a reduced pill burden for patients with idiopathic pulmonary fibrosis (IPF) People with IPF now have the option of taking one Esbriet... Read more

June 26, 2017 Bio/Pharma/CRO PR/Corporate

Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more

June 26, 2017 Bio/Pharma/CRO PR/Corporate

Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more

June 23, 2017 PR/Corporate

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers

Basel, 23 June 2017 Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia,... Read more

June 23, 2017 Clinical Research/Diagn. PR/Corporate Product Launch

Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma

Basel, 23 June 2017 Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens  People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related quality of... Read more